Investors Annual Results-Cover tab

Annual results 2023-Jan312024

介质继电器，介质继电器

English（PDF0.3MB）｜Deutsch（PDF0.3MB）｜FranCaais（PDF0.3MB）

Condensed financial report（PDF0.6MB）

Webcast and presentation

Watch the webcast

MP3 34MB

PDF5.5MB

Read the transcript

Novartis Q4 2023 Impact and Sustainability Update（PDF 0.6MB）

Download 2023epidemiology data（PDF1.1MB）

 

Shanelle Gabriel spending time with her father in New York

Novartis in Society Integrated Report2023

This report covers our business，strategy and performance。It high lights progress against our ESG targets and describes how we create sustainable value for diverse stakeholders。It follows requirements of the Swiss Code of Obligations and various voluntary reporting frameworks and standards。
 

PDF8.4MB下载集成报告

查看online summary
K.Balamani with her daughter at home in Sollakpally，near Hyderabad，India

Annual Report 2023 and US Securities&Exchange Commission Form 20-F 2023

These reports provide a comprehensive overview of Novartis，including our company structure，corporate governance，operating and financial results，and compensation practices。They are filed with the SIX Swiss Exchange in Switzerland the Securities and Exchange Commission in the US。
 

Annual Report2023（PDF3.7MB）｜Form20-F2023（PDF3.5MB）

顺序，顺序，顺序

Annual results 2023-Jan312024

关键帧配置1个

内容操作2

 FY2023
（USD m）		FY2022
（USD m）		%change
（USD/cc）
Net sales45440422068（cc:10）
操作income9769794623（cc:39）
Net income8572604942（cc:62）
EPS（USD）4.132.7749（cc:70）
Free cash flow11360121239

核心，核心		   
操作income133721479411（cc:18）
Net income134461194613（cc:19）
EPS（USD）6.475.4818（cc:25）
  1. Constant currencies（cc），core results and free cash flow are non-IFRS measures。An explanation of non-IFRS measures can be found on page49of the Condensed Financial Report。Unless otherwise noted，all growth rates in this Release refer to same period in prior year。
  2. As defined on page37of the Condensed Financial Report，Continuing operations include the retained business activities of Novartis，comprising the innovative medicines business and the continuing Corporate activities and Discontinued operational results from the Sandoz business。

介质继电器，介质继电器

English（PDF0.3MB）｜Deutsch（PDF0.3MB）｜FranCaais（PDF0.3MB）

Condensed financial report（PDF0.6MB）

Watch the webcast

MP3 34MB

PDF5.5MB

Read the transcript

Novartis Q4 2023 Impact and Sustainability Update（PDF 0.6MB）

Download 2023epidemiology data（PDF1.1MB）

Annual results 2022-Feb012023

关键帧配置1个FY2022
（USD m）		FY2021
（USD m）		%change
（USD/cc）
Net sales5054551626-2（cc:4）
操作income919711689-21（cc:-13）
Net income695524018-71（cc:-67）
EPS（USD）3.1910.71-70（cc:-66）
Free cash flow1194513282-10

核心，核心		   
操作income16665165880（cc:8）
Net income1335214094-5（cc:3）
EPS（USD）6.126.29-3（cc:6）
  1. Constant currencies（cc），core results and free cash flow are non-IFRS measures。An explanation of non-IFRS measures can be found on page50of the Condensed Financial Report。Unless otherwise noted，all growth rates in this Release refer to same period in prior year。

介质继电器，介质继电器

English（PDF0.3MB）｜Deutsch（PDF0.3MB）｜FranCaais（PDF0.3MB）

Condensed financial report（PDF0.5MB）

PDF5.1MB

Download the podcast（MP345MB）

Read the presentation transcript

Novartis ESG Update Q4 2022（PDF 0.9MB）

Annual results 2021-Feb020222

关键帧配置1个FY2021
（USD m）		FY2020
（USD m）		%change
（USD/cc）
Net sales51626486596（cc:4）
操作income11689115215（cc:13）
Net income240188071198（cc:195）
EPS（USD）10.713.55202（cc:200）
Free cash flow132821169114

核心，核心		   
操作income16588154168（cc:6）
Net income14094115587（cc:5）
EPS（USD）6.295.789（cc:7）
  1. Constant currencies（cc），core results and free cash flow are non-IFRS measures。An explanation of non-IFRS measures can be found on page50of the Condensed Financial Report。Unless otherwise noted，all growth rates in this Release refer to same period in prior year。

介质继电器，介质继电器

English（PDF0.3MB）｜Deutsch（PDF0.3MB）｜FranCaais（PDF0.3MB）

Condensed financial report（PDF0.5MB）

Download the podcast（MP3 43MB）

Read the presentation transcript

PDF4.9MB

Novartis ESG Update-February032022（PDF1.7MB）

Annual results 2020-Jan262021

关键帧配置2

内容操作1个

 FY2020
（USD m）		FY2019
（USD m）		%change
（USD/cc）
Net sales48659474453（cc:3）
操作income1152908612（cc:19）
Net income8071714713（cc:20）
EPS（USD）3.553.1214（cc:21）
Free cash flow1169112937-10

核心，核心		   
操作income15416141129（cc:13）
Net income11558121049（cc:12）
EPS（USD）5.785.289（cc:13）
  1. Refers to continuing operations as defined on page43of the Condensed Financial Report，excludes Alcon，includes the businesses of Innovative Medicines and Sandoz，as well as the continuing corporate functions。
  2. Constant currencies（cc），core results and free cash flow are non-IFRS measures。An explanation of non-IFRS measures can be found on page55of the Condensed Financial Report。Unless otherwise noted，all growth rates in this Release refer to same period in prior year。

介质继电器，介质继电器

English（PDF0.2MB）｜Deutsch（PDF0.2MB）｜FranCaais（PDF0.2MB）

Condensed financial report（PDF0.6MB）

Annual results 2019-Jan292020

关键帧配置2

内容操作1个

 FY2019
（USD m）		FY2018
（USD m）		%change
（USD/cc）
Net sales47445447516（cc:9）
操作income908684038（cc:14）
Net income714712800-44（cc:-41）
EPS（USD）3.125.52-43（cc:-40）
Free cash flow129371125615

核心，核心		   
操作income141121255712（cc:17）
Net income121041092011（cc:15）
EPS（USD）5.284.7112（cc:17）
  1. Refers to continuing operations as defined on page45 of the Condensed Financial Report，excludes Alcon，includes the businesses of Innovative Medicines and Sandoz（including the USgeneric oral solids and dermatology portfolio），as well as the continuing corporate functions。
  2. Constant currencies（cc），core results and free cash flow are non-IFRS measures。An explanation of non-IFRS measures can be found on page58of the Condensed Financial Report。Unless otherwise noted，all growth rates in this Release refer to same period in prior year。

介质继电器，介质继电器

English（PDF0.1MB）｜Deutsch（PDF0.1MB）｜FranCaais（PDF0.1MB）

Condensed financial report（PDF0.6MB）

Disclaimer:The information in the presentations on these pages was factually accurate on the date of publication。These presentations remain on the Novartis website for historical purposes only。Novartis assumes no responsibility to update the information to reflect subsequent developments。Readers should not rely upon the information in these pages as current or accurate after their publication dates。